Switching Between Infliximab, Biosimilars Deemed Safe, Effective in Patients With IBD

Most patients remained on infliximab biosimilars during the follow-up period and the number of switches was not independently linked to infliximab persistence after adjusting for confounders.

Related Keywords

Edinburgh ,City Of ,United Kingdom ,Beatriz Gros ,European Medicines Agency ,Drug Administration ,United European Gastroenterology ,Western General Hospital ,